Clinical trial NCT06086548: Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
Official title: Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Facioscapulohumeral Muscular Dystrophy
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
Collaborators: name: University of Modena and Reggio Emilia
name: Federico II University
First posted: 2023-10-17
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Recruitment of participants will be conducted at Centre Hospitalier Universitaire d'Angers. All subjects will be clinically evaluated on the basis of the CCEF evaluation protocol. Informed consent will be obtained according to the declaration of Helsinki by each participant after explanations on the research protocol and scientific aims.

Patients will be excluded when they have other disorders that will influence the measurements. Age- and sex-matched healthy subjects will be included through specific calls depending on age.

Brief summary: The pathogenesis of facioscapulohumeral dystrophy (FSHD), one of the most prevalent types of inherited muscle disease, is unknown. The reasons underlying its significant clinical heterogeneity, incomplete penetrance, and sex specific differences in the age of onset, are not currently understood. While metabolic changes associated with this disease have so far deserved little attention, recent studies have pinpointed significant metabolic dysregulation as an emerging driving mechanism in the pathophysiology of this untreatable disease. To test this hypothesis, we will perform a deep metabolic phenotyping in a large cohort of highly clinically characterized FSHD patients at different stage of disease and age/sex-matched controls by state-of-art plasma metabolomic and mitochondrial biomarker profiling. These data will allow attributing specific metabolomic signatures to different stages of the disease in each sex. Metabolic pathway analysis will allow gaining insights into the type of metabolic dysregulation associated with the disease pathogenesis, leading to the identification of targeted metabolic/nutritional interventions and biomarker discovery.


Eligibility criteria: Inclusion Criteria:

* participant fasting for at least 8 h at the time of blood sampling
* patient with a molecular diagnosis of FSHD (know number of D4Z4 contractions)
* patient with a typical FSHD presentation (at least facial, pelvic ans scapular girdles signs)
* patient with a preserved ability to ambulate at the time of the selection (use of a cane is allowed)

Exclusion Criteria:

* Severe cardiac and respiratory dysfunction.
* Presence of severe systemic diseases unrelated to FSHD.
* Presence of uncontrolled diabetes or hypothyroidism.
* Alcohol or toxic abuse.

Primary outcomes:
measure: metabolic profiling
timeFrame: results should be obtained within 3 months following the inclusion of the last participant
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: